Lanadelumab, a monoclonal antibody acting as inhibitor of active plasma kallikrein [93], has been recently added among therapeutic strategies for long-term prophylaxis in patients aged ≥ 12 years with HAE due to C1-INH-HAE [94]. The gene discussed is KLK4; the disease is hereditary angioedema.